{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:16:33Z","timestamp":1794352593370,"version":"4.9.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To report a case of a patient showing bilateral corneal opacities after amantadine chronic treatment for Parkinson\u2019s Disease (PD) and corneal edema associated with intra-epithelial and -endothelial depositions. After amantadine discontinuation a complete clinical remission with only a\u00a0partial ultrastructural corneal recovery was reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We describe a 78-year-old man with non-medical-responding bilateral corneal edema in treatment with systemic Amantadine for PD. In vivo confocal Microscopy (IVCM) analysis revealed hyperreflective particles at the epithelial level and expanded hyperreflective keratocyte and a disarrangement of stromal lamellae; endothelial cells showed hyperreflective intracellular inclusions in central and in peripheral areas with central polymegatism and pleomorphism. After 1 and 6\u00a0months the amantadine discontinuation, the absence of bilateral corneal edema and opacities were noted at the slit lamp\u00a0examination, associated with the disappearance of epithelial and stromal abnormalities, but the persistence of endothelial hyperreflective deposits with a pleomorphism and polymegatism worsening at the IVCM\u00a0exam.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The evaluation of a patient\u2019s cornea 6\u00a0months after the discontinuation of systemic amantadine therapy showed a clinical complete remission, with a complete resolution of the bilateral corneal oedema. On the other hand, ultrastructurally, amantadine toxicity is a completely reversible phenomenon at the epithelial level; conversely IVCM showed persistent endothelial degradation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02410-1","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T13:03:52Z","timestamp":1652187832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Amantadine therapy for Parkinson\u2019s Disease: In Vivo Confocal Microscopy corneal findings, case report and revision of literature"],"prefix":"10.1186","volume":"22","author":[{"given":"Michela","family":"Cennamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dragotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Favuzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-6363","authenticated-orcid":false,"given":"Rita","family":"Mencucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"2410_CR1","doi-asserted-by":"crossref","unstructured":"Schwab RS, England AC, Poskanzer DC, et al. Amantadine in the treatment of Parkinson\u2019s disease. JAMA J Am Med Assoc. 1969.","DOI":"10.1001\/jama.1969.03160070046011"},{"key":"2410_CR2","doi-asserted-by":"crossref","unstructured":"Lee PY, Tu HP, Lin CP, et al. Amantadine use as a risk factor for Corneal Edema: a nationwide cohort study in Taiwan. Am J Ophthalmol. 2016;171:122\u20139.","DOI":"10.1016\/j.ajo.2016.08.034"},{"key":"2410_CR3","doi-asserted-by":"crossref","unstructured":"Dudley CE, Morell AJ, Duffey ME, et al. Effects of amantadine on corneal endothelium. Exp Eye Res. 2019;181:208\u201312.","DOI":"10.1016\/j.exer.2019.02.010"},{"key":"2410_CR4","doi-asserted-by":"crossref","unstructured":"Hotehama A, Mimura T, Usui T, et al. Sudden onset of amantadine-induced reversible bilateral corneal edema in an elderly patient: case report and literature review. Jpn J Ophthalmol. 2011.","DOI":"10.1007\/s10384-010-0888-8"},{"key":"2410_CR5","doi-asserted-by":"crossref","unstructured":"Sie NM, Yam GH, Soh YQ, et al. Regenerative capacity of the corneal transition zone for endothelial cell therapy. Stem Cell Res Ther. 2020;11(1):523.","DOI":"10.1186\/s13287-020-02046-2"},{"key":"2410_CR6","doi-asserted-by":"crossref","unstructured":"Chang KC, Jeong JH, Kim MK, et al. The effect of amantadine on corneal endothelium in subjects with Parkinson\u2019s disease. Ophthalmology. 2010;117:1214\u20139.","DOI":"10.1016\/j.ophtha.2009.10.039"},{"key":"2410_CR7","doi-asserted-by":"crossref","unstructured":"Daggumilli S, Vanathi M, Ganger A, et al. Corneal evaluation in patients with parkinsonism on long-term amantadine therapy. Cornea. 2019;38(9):1131\u20136.","DOI":"10.1097\/ICO.0000000000001951"},{"key":"2410_CR8","doi-asserted-by":"crossref","unstructured":"Yoshinaka A, Chikama T, Kiuchi Y. Amantadine can induce intra-epithelial deposition in the cornea. Am J Ophthalmol Case Rep. 2020;19:100852.","DOI":"10.1016\/j.ajoc.2020.100852"},{"key":"2410_CR9","doi-asserted-by":"crossref","unstructured":"Chang KC, Kim MK, Wee WR, et al. Corneal endothelial dysfunction associated with amantadine toxicity. Cornea. 2008;27:1182\u20135.","DOI":"10.1097\/ICO.0b013e318180e526"},{"key":"2410_CR10","doi-asserted-by":"crossref","unstructured":"Mancera N, Wadia HP. Corneal Edema associated with systemic dopaminergic agents. Cornea. 2019;38(8):1040\u20132.","DOI":"10.1097\/ICO.0000000000001941"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02410-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T13:09:07Z","timestamp":1652188147000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02410-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2410"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02410-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"29 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent to publish this information was obtained from study participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}